New Oral Drug Delivery Partnership Gives Wider Access to IntelliCap Technology
News Nov 01, 2014
Medimetrics has established a partnership with pharmaceutical services business, Scintipharma, to deliver wider access to its technology. Both companies are exhibiting at this year’s American Association of Pharmaceutical Scientists (AAPS) congress in Chicago, USA, 2-6 November 2014.
IntelliCap is an extremely powerful and comprehensive tool for the early-stage development of new drugs or for the life cycle management of existing drugs. Its use in drug trials enables researchers to conduct advanced site absorption studies in the gastro-intestinal (GI) tract, which deliver more complete and robust results on the merits and properties of the drug product. The outcome is a more cost-efficient product development programme.
As chief executive officer Dr Olaf Weiner explained: “Patients prefer to take drugs orally, so manufacturers need to understand exactly how a drug formulation performs as it delivers its dosage at various points in the GI tract. IntelliCap has a significant role to play in helping direct future investment by providing speedy validation of a compound’s suitability for moving towards approval, or indicating its limitations.
“Combining IntelliCap’s unique properties with the established expertise of Scintipharma, we can provide expanded access to services that directly benefit the customer. This will further accelerate the formulation development process and provide early identification of those products most likely to succeed.”
Scintipharma, based in Kentucky, USA, was founded more than 22 years ago by scientists Walter Doll and Erik Sandefer. As Dr Doll commented: “Our mission has always been to help improve the early drug development process so that companies can optimize the efficiency of a new formulation, or avoid spending time and resources on products with little chance of success.
“The partnership with Medimetrics builds on our existing strengths of outstanding service and offering innovative products. The opportunity to include the IntelliCap products expands the choice and breadth of services available to customers.”
Medimetrics offers two IntelliCap systems: IntelliCap CR (controlled release), for the targeted delivery of drugs with any programmed delivery profile; and the new IntelliCap FR (fast release), for the targeted delivery of any type of drug payload, including solids and powders. The technology’s unique properties also include continuous real-time measurement and reporting of the pH conditions within the GI tract.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE